当前位置: X-MOL 学术Bio-Medical Mater. Eng. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Multiple platelet-rich plasma preparations can solubilize freeze-dried chitosan formulations to form injectable implants for orthopedic indications.
Bio-Medical Materials and Engineering ( IF 1 ) Pub Date : 2019-01-01 , DOI: 10.3233/bme-191058
Leili Ghazi Zadeh 1 , Anik Chevrier 2 , Martin Lamontagne 3 , Michael D Buschmann 4 , Caroline D Hoemann 4 , Marc Lavertu 2
Affiliation  

BACKGROUND Platelet-rich plasma (PRP) has been used to solubilize freeze-dried chitosan (CS) formulations to form injectable implants for tissue repair. OBJECTIVE To determine whether the in vitro performance of the formulations depends on the type of PRP preparation used to solubilize CS. METHODS Formulations containing 1% (w/v) CS with varying degrees of deacetylation (DDA 80.5-84.8%) and number average molar mass (Mn 32-55 kDa), 1% (w/v) trehalose and 42.2 mM calcium chloride were freeze-dried. Seven different PRP preparations were used to solubilize the formulations. Controls were recalcified PRP. RESULTS CS solubilization was achieved with all PRP preparations. CS-PRP formulations were less runny than their corresponding PRP controls. All CS-PRP formulations had a clotting time below 9 minutes, assessed by thromboelastography, while the leukocyte-rich PRP controls took longer to coagulate (>32 min), and the leukocyte-reduced PRP controls did not coagulate in this dynamic assay. In glass culture tubes, all PRP controls clotted, expressed serum and retracted (43-82% clot mass lost) significantly more than CS-PRP clots (no mass lost). CS dispersion was homogenous within CS-PRP clots. CONCLUSIONS In vitro performance of the CS-PRP formulations was comparable for all types of PRPs assessed.

中文翻译:

多种富含血小板的血浆制剂可以溶解冻干的壳聚糖制剂,形成用于骨科适应症的可注射植入物。

背景技术富血小板血浆(PRP)已被用于溶解冷冻干燥的壳聚糖(CS)制剂以形成用于组织修复的可注射植入物。目的确定制剂的体外性能是否取决于用于溶解CS的PRP制剂的类型。方法含有1%(w / v)CS的脱乙酰度(DDA 80.5-84.8%)和数均摩尔质量(Mn 32-55 kDa),1%(w / v)海藻糖和42.2 mM氯化钙的制剂冻干。七种不同的PRP制剂用于溶解制剂。对照是重新钙化的PRP。结果所有PRP制剂均实现了CS增溶。CS-PRP制剂比相应的PRP对照剂流鼻涕。根据血栓弹力图评估,所有CS-PRP制剂的凝结时间均低于9分钟,而富含白细胞的PRP对照需要更长的凝结时间(> 32分钟),而通过白细胞还原的PRP对照在此动态测定中不凝结。在玻璃培养管中,与CS-PRP凝块(无质量损失)相比,所有凝结,表达血清和缩回的PRP对照(凝块质量损失43-82%)显着更多。CS分散在CS-PRP凝块内是均匀的。结论CS-PRP制剂的体外性能与所有评估的PRP类型均相当。
更新日期:2019-11-01
down
wechat
bug